TBx increased to 23.9% with the IBx and to 32.6% for the RBx (p <0.001). It was 29. 0% and 45.5%, respectively in G1; 20.0% and 33.3% in G2; 40.0% and 38.9% in G3, and 0% and 0% in G4: p <0.001.
INTRODUCTION AND OBJECTIVES:
The aim of this study was to investigate the characteristics of PCa still diagnosed with SBx without a previous MRI and to compare these features with those receiving an MRI-guided approach METHODS: We identified 3,167 men diagnosed with PCa by SBx without a previous MRI for a suspicion of PCa (no-MRI group) at a single tertiary care referral Centre between 2010 and 2018. We then identified 299 men with PCa diagnosed by an upfront MRI and subsequent target Bx (TBx) in addition to SBx (MRI group). Loess functions graphically depicted the year-by-year trends in Gleason score (GS) distribution at SBx. Multivariate logistic regression analyses (MVA) were used to assess the predicted risk of having clinically significant PCa (csPCa) in the two groups after accounting for age, PSA, clinical stage (T1 vs T2 vs T3) and year of biopsy (yob). We then investigated the trend of the probability of no-MRI group to harbour csPCa over time as compared to the MRI group, after accounting for several confounders. Loess functions were used to plot all the graphs. Changes over time were analysed using linear regression RESULTS: Overall, in the no-MRI group, 1427 (45%), 966 (31%) and 774 (24%) had GS 3þ3, 3þ4 and !4þ3 at SBx. The rate of GS 3þ3 decreased from 55% in 2010 to 13% in 2018 (p<0.001). Conversely, the rate of GS!4þ3 increased from 19% in 2010 to 57% in 2018 (p<0.001; Fig 1a) . At MVA, age (OR: 1.05), PSA (OR:1.04), clinical stage (OR T2: 2.26; T3: 6.02) and yob (OR:1.21) were significantly associated with the probability to harbour csPCa at SBx (all p<0.001). The probability of csPCa increased over time from 15% in 2010 to roughly 45% in 2018 in men not receiving any MRI (Fig 1b) . Loess function showed a comparable trend also in the MRI group (Fig 1b) where men referred to MRI are at even higher risk of csPCa regardless of imaging findings CONCLUSIONS: The rate of GS 3þ3 in patients referred for SBx without a previous MRI has decreased over time, while a significant increase of GS!4þ3 was observed. In both groups a significant increase in the detection of csPCa was observed. These data suggest an improved patient selection over time by physicians who are currently referring to both imaging guided and blinded biopsy patients at higher risk of csPCa. This is leading to a trend towards detection of more aggressive disease. greater ability to localize areas more likely to harbour clinically significant prostate cancer (csPCa). However, the predictive ability of MRI may vary according to prostatic zone (peripheral vs transitional) and sectors. The aim of this study was to assess the performance of mpMRI in detecting csPCa according to the location of the index lesion (IL).
METHODS: We identified 862 patients who underwent MRI of the prostate with subsequent fusion targeted and concomitant systematic biopsy at two tertiary referral Centres between 2013 and 2018. Included men either were biopsy naive, or had a previous biopsy. All men had a negative digital rectal examination and had a single MRI lesion. MRIs were scored according to the PIRADS system by expert radiologists. The study outcome was csPCa at targeted biopsy (TBx), defined as Gleason score at biopsy!3þ4. The rates of csPCa according to both prostatic zone, namely peripheral (PZ) vs transitional (TZ) and segments, namely base vs mid vs apex were calculated. Two multivariable logistic regression models (MVA) were developed to assess the relationship between lesion location at MRI and the study outcome: Model 1 using age at biopsy, PSA density (ng/ml/ml), PIRADS score (<4 vs!4) and lesion location at MRI (TZ vs PZ) as covariates; Model 2 including lesion location classified as base vs mid vs apex of the prostate and accounting for the same confounders.
RESULTS: Overall, 599 (69%) and 263 (31%) patients had a lesion in the PZ and TZ, respectively. Similarly, 166 (19%) , 483 (56%), 213 (25%) patients had a lesion at the base, middle and apex segment of the prostate, respectively. Overall, 49% (n[419) men were diagnosed with csPCa and 44% (n[379) had csPCa at TBx alone. The detection rate of csPCa at TBx was 26 (n[100) and 74% (n[279) in TZ vs PZ, respectively (p[0.001). The detection rate of csPCa at TBx was 16 (n[62), 57 (n[216), 27% (n[101) for the base vs. middle vs. apex of the prostate, respectively (p[0.02). At MVA, lesions located in the TZ were less likely to be associated with csPCa (OR: 0.8; p[0.02), while ILs at the middle part of the prostate (OR: 1.5; p[0.04) were positively associated with the presence of csPCa even after accounting for confounders.
CONCLUSIONS: The accuracy of MRI in identifying csPCa is lower for lesions located within the TZ and higher for those in the mid part of the of the prostate. This should be taken into account when interpreting a positive MRI report during the clinical decision making process potentially leading to prostate biopsy.
